Aurora kinase mRNA expression is reduced with increasing gestational age and in severe early onset fetal growth restriction

Sally Beard; Natasha Pritchard; Natalie Binder; Karen Schindler; Natasha De Alwis; Tu'uhevaha J Kaitu'u-Lino; Stephen Tong; Natalie J Hannan

Journal article

Aurora kinase mRNA expression is reduced with increasing gestational age and in severe early onset fetal growth restriction

Sally Beard, Natasha Pritchard, Natalie Binder, Karen Schindler, Natasha De Alwis, Tu'uhevaha J Kaitu'u-Lino, Stephen Tong, Natalie J Hannan

PLACENTA | W B SAUNDERS CO LTD | Published : 2020

DOI: 10.1016/j.placenta.2020.04.012

Abstract

INTRODUCTION: Oxidative damage and biochemical ageing are implicated in placental dysfunction and potentially fetal death. Cellular senescence may play a role in the pathophysiology of fetal growth restriction (FGR) and preeclampsia (PE). Aurora kinases (AURKA, B and C) are important regulators of cellular division in mitosis and meiosis with implications in cellular senescence. We aimed to investigate whether aurora kinase expression is altered with placental dysfunction or placental ageing. METHODS: Placenta and blood was obtained across gestation from pregnancies complicated by PE, FGR or both PE and FGR, as well as gestation-matched control samples. Expression of AURKA, B and C mRNA was ..

View full abstract

University of Melbourne Researchers

Tu'uhevaha Kaitu'u-Lino Author Obstetrics and Gynaecology Royal Women's Hospital/Mercy

Stephen Tong Author Obstetrics and Gynaecology Royal Women's Hospital/Mercy

Natasha Pritchard Author Obstetrics and Gynaecology Royal Women's Hospital/Mercy

Natalie Hannan Author Obstetrics and Gynaecology Royal Women's Hospital/Mercy

Sally Beard Author Obstetrics and Gynaecology Royal Women's Hospital/Mercy

Related Projects (4)

TRANSLATING NEW THERAPEUTICS AND DIAGNOSTICS FOR MAJOR PREGNANCY COMPLICATIONS

My research is focussed on tackling major complications of pregnancy that are a threat to the lives of both mother’s and babies. We are deve..

DEVELOPMENT OF NOVEL THERAPEUTICS TO PREVENT OR TREAT PREECLAMPSIA

Preeclampsia, a major pregnancy complication, affects ~3-8% of pregnancies. There is no cure. We have developed new strategies to tackle the..

IDENTIFICATION OF WHICH FETAL GROWTH CHARTS AND BIRTHWEIGHT CENTILES ARE BEST ABLE TO IDENTIFY INFANTS AND MOTHERS AT RISK OF ADVERSE OBSTETRIC AND PERINATAL OUTCOMES

Preeclampsia, one of the most serious complications of pregnancy, affects around 3-8% of all pregnancies. Sadly, there is no treatment. We h..

NEW DIAGNOSTICS TO PREDICT PREECLAMPSIA AND FETAL GROWTH RESTRICTION

Grants

Awarded by NHMRC

Funding Acknowledgements

We would like to thank the research midwives, Gabrielle Pell, Genevieve Christophers, Rachel Murdoch and Debra Jinks, obstetrics and midwifery staff, and patients at the Mercy Hospital for Women for provision placental tissue and blood samples. The NHMRC provided salary support (TKL; #1159261, ST; #1136418 and NJH; #1146128) and post-graduate scholarship support (NP; #1150828).